HomeCompareGRMCX vs JNJ

GRMCX vs JNJ: Dividend Comparison 2026

GRMCX yields 0.26% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRMCX wins by $15.00 in total portfolio value
10 years
GRMCX
GRMCX
● Live price
0.26%
Share price
$22.85
Annual div
$0.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$26.67
Full GRMCX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — GRMCX vs JNJ

📍 GRMCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRMCXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRMCX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRMCX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRMCX
Annual income on $10K today (after 15% tax)
$22.28/yr
After 10yr DRIP, annual income (after tax)
$22.67/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $680.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRMCX + JNJ for your $10,000?

GRMCX: 50%JNJ: 50%
100% JNJ50/50100% GRMCX
Portfolio after 10yr
$20.0K
Annual income
$427.22/yr
Blended yield
2.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GRMCX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRMCX buys
0
JNJ buys
0
No recent congressional trades found for GRMCX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRMCXJNJ
Forward yield0.26%3.36%
Annual dividend / share$0.06$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$20.0K$20.0K
Annual income after 10y$26.67$827.78
Total dividends collected$265.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GRMCX vs JNJ ($10,000, DRIP)

YearGRMCX PortfolioGRMCX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,726$26.21$10,676$355.77+$50.00GRMCX
2$11,503$26.28$11,407$389.39+$96.00GRMCX
3$12,335$26.34$12,198$426.53+$137.00GRMCX
4$13,225$26.40$13,056$467.62+$169.00GRMCX
5$14,177$26.45$13,987$513.12+$190.00GRMCX
6$15,196$26.50$14,998$563.56+$198.00GRMCX
7$16,286$26.54$16,098$619.52+$188.00GRMCX
8$17,453$26.59$17,295$681.69+$158.00GRMCX
9$18,701$26.63$18,599$750.82+$102.00GRMCX
10$20,037$26.67$20,022$827.78+$15.00GRMCX

GRMCX vs JNJ: Complete Analysis 2026

GRMCXStock

The investment seeks to provide investment results that correspond to the price and yield performance of publicly traded common stocks, as represented by the Standard & Poor's 500® Index (S&P 500 Index). The fund employs a “passive” management approach, investing in a portfolio of assets whose performance the subadviser expects to match approximately the performance of the index. It invests at least 80% of its net assets in equity securities of companies included in the index. The index is composed of approximately 500 common stocks selected by Standard & Poor’s, most of which are listed on the New York Stock Exchange or NASDAQ.

Full GRMCX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this GRMCX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRMCX vs SCHDGRMCX vs JEPIGRMCX vs OGRMCX vs KOGRMCX vs MAINGRMCX vs ABBVGRMCX vs MRKGRMCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.